33.09
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$33.50
Offen:
$33.66
24-Stunden-Volumen:
1.38M
Relative Volume:
0.49
Marktkapitalisierung:
$4.54B
Einnahmen:
$264.79M
Nettoeinkommen (Verlust:
$-14.36M
KGV:
-300.82
EPS:
-0.11
Netto-Cashflow:
$-28.11M
1W Leistung:
+4.38%
1M Leistung:
+18.18%
6M Leistung:
+65.53%
1J Leistung:
+130.27%
Tg Therapeutics Inc Stock (TGTX) Company Profile
Firmenname
Tg Therapeutics Inc
Sektor
Branche
Telefon
(212) 554-4484
Adresse
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Vergleichen Sie TGTX mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
TGTX
Tg Therapeutics Inc
|
33.09 | 4.54B | 264.79M | -14.36M | -28.11M | -0.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-10-29 | Eingeleitet | TD Cowen | Buy |
2023-08-02 | Hochstufung | Goldman | Sell → Neutral |
2023-06-26 | Fortgesetzt | Jefferies | Buy |
2022-05-20 | Eingeleitet | BofA Securities | Underperform |
2022-02-23 | Bestätigt | B. Riley Securities | Buy |
2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
2021-04-20 | Eingeleitet | Goldman | Neutral |
2021-04-19 | Bestätigt | H.C. Wainwright | Buy |
2020-09-01 | Eingeleitet | JP Morgan | Overweight |
2020-08-11 | Bestätigt | H.C. Wainwright | Buy |
2020-06-05 | Eingeleitet | Evercore ISI | Outperform |
2020-01-17 | Bestätigt | H.C. Wainwright | Buy |
2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
2019-02-06 | Fortgesetzt | Jefferies | Buy |
2018-09-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
2018-03-09 | Bestätigt | B. Riley FBR, Inc. | Buy |
2017-12-01 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
2017-11-14 | Fortgesetzt | H.C. Wainwright | Buy |
2017-04-25 | Eingeleitet | Jefferies | Buy |
2017-03-06 | Bestätigt | FBR & Co. | Outperform |
2016-10-06 | Fortgesetzt | Brean Capital | Buy |
2016-05-27 | Eingeleitet | SunTrust | Buy |
2015-12-01 | Eingeleitet | FBR Capital | Outperform |
2015-09-09 | Eingeleitet | Raymond James | Strong Buy |
2015-08-12 | Fortgesetzt | H.C. Wainwright | Buy |
2015-06-19 | Bestätigt | Brean Capital | Buy |
2014-12-11 | Bestätigt | ROTH Capital | Buy |
2014-12-10 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
Stratos Wealth Advisors LLC Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
SG Americas Securities LLC Has $233,000 Stake in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Institutional investors are TG Therapeutics, Inc.'s (NASDAQ:TGTX) biggest bettors and were rewarded after last week's US$199m market cap gain - Simply Wall St
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
TGTX March 28th Options Begin Trading - Nasdaq
Symphony Financial Ltd. Co. Acquires New Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Rating Lowered to "Sell" at StockNews.com - MarketBeat
Precision Wealth Strategies LLC Buys Shares of 17,608 TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
Nisa Investment Advisors LLC Buys 2,803 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Trading (TGTX) With Integrated Risk Controls - Stock Traders Daily
All You Need to Know About TG Therapeutics (TGTX) Rating Upgrade to Buy - MSN
TG Therapeutics (NASDAQ:TGTX) Stock Price Up 6.8%Here's What Happened - MarketBeat
Why TGTX Stock Is Rallying Today - MSN
TG Therapeutics: Entering 2025 With Increased Investor Expectations (NASDAQ:TGTX) - Seeking Alpha
Cantor Fitzgerald Weighs in on TG Therapeutics FY2025 Earnings - Defense World
Assenagon Asset Management S.A. Decreases Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - MarketBeat
TG Therapeutics: 2025 Revenues Will Smash Expectations (NASDAQ:TGTX) - Seeking Alpha
12 Hot Stocks to Buy According to Analysts - Insider Monkey
Here’s Why Analysts Are Bullish on TG Therapeutics, Inc. (TGTX) - Insider Monkey
TG Therapeutics (TGTX) Moves 7.5% Higher: Will This Strength Last? - MSN
(TGTX) Trading Signals - Stock Traders Daily
Brookstone Capital Management Acquires 624 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
FY2024 EPS Forecast for TG Therapeutics Increased by Analyst - Defense World
Is TG Therapeutics Inc. (TGTX) Among Tuesday’s Top Gainers? - MSN
TG Therapeutics FY2024 EPS Forecast Raised by HC Wainwright - MarketBeat
TG Therapeutics Provides Preliminary Fourth Quarter and Full-Year Financial Results in SEC Filing - Defense World
TG Therapeutics: Cash Positive But Playing Defense (Rating Downgrade) (NASDAQ:TGTX) - Seeking Alpha
TG Therapeutics FY2025 EPS Forecast Raised by HC Wainwright - MarketBeat
TG Therapeutics' (TGTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise - MSN
Exploring Three High Growth Tech Stocks In The United States - Yahoo Finance
Have Insiders Sold TG Therapeutics Shares Recently? - Simply Wall St
Expert Outlook: TG Therapeutics Through The Eyes Of 5 Analysts - Benzinga
TG Therapeutics stock rises on strong Q4 and full-year revenue - Investing.com Australia
10 Firms Post Impressive Gains on Tuesday - Insider Monkey
TG Therapeutics Reports Strong Revenue and Future Goals - TipRanks
TG Therapeutics Shares Climb 7% as Sales Grow for Multiple Sclerosis Drug - MarketWatch
TG Therapeutics Provides Preliminary Fourth Quarter and - GlobeNewswire
TG Therapeutics (NASDAQ:TGTX) Shares Gap UpHere's Why - MarketBeat
TG Therapeutics projects $540 million in 2025 revenue By Investing.com - Investing.com Nigeria
What's Going On With TG Therapeutics Stock Tuesday? - Benzinga
TG Therapeutics says 2024 Briumvi sales topped expectations - MSN
TG Therapeutics stock rises on strong Q4 and full-year revenue By Investing.com - Investing.com South Africa
TG Therapeutics stock gains on Briumvi sales (TGTX:NASDAQ) - Seeking Alpha
TG Therapeutics projects $540 million in 2025 revenue - Investing.com
Finanzdaten der Tg Therapeutics Inc-Aktie (TGTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):